This article is more than 5 years old. Information may no longer be current.
Complete skin clearance represents meaningful endpoint for patients with psoriasis
Click Here to Manage Email Alerts
Complete skin clearance in patients with psoriasis was a clinically meaningful endpoint and outcome, with no impairment on their health-related quality of life, according to recently published study results.
Researchers studied pooled data from the nonplacebo cohorts of three phase 3 trials of brodalumab (Valeant) in patients with moderate-to-severe plaque psoriasis. They compared results for patients with complete skin clearance, determined by Psoriasis Area and Severity Index (PASI) 100 or static Physician Global Assessment score of 0, with patients who did not have complete skin clearance, determined by a PASI 75 to <100 or static Physician Global Assessment score of 1.
The researchers found that 45% of patients who achieved a PASI 100 and 8% of patients achieving PASI 75 to < 100 had a Psoriasis Symptom Inventory score of 0 (P < .001). In addition, 80% of the PASI 100 patients and 55% of the PASI 75 to < 100 patients achieved a Dermatology Life Quality Index score of 0/1.
“PASI 100 resulted in incremental improvement over PASI 90 to < 100 (incremental differences of 28% for Psoriasis Symptom Inventory score 0 and 18% for Dermatology Life Quality Index score 0),” the researchers wrote.
Physician Global Assessment scores 0 vs. 1 showed similar results.
“Patients with psoriasis who respond to treatment without complete clearance (eg, PASI 75) may still have substantial residual disease and resultant effect on [health-related quality of life (QoL)] and objective signs and symptoms of psoriasis,” the researchers wrote. “Evidence from clinical and observations studies shows that achieving completely clear skin is clinically meaningful in terms of both disease severity and patient-reported [health-related QoL].”
“Overall, a higher proportion of patients achieving complete clearance than those who were labeled as responders, but were not clear, had no impairment in dermatology-specific [health-related QoL] and experienced no psoriasis symptoms,” the researchers concluded. – by Bruce Thiel
Disclosure: Strober reports serving as an adviser, paid speaker, consultant and/or principle investigator for CORRONA Psoriasis registry, AbbVie, Amgen, Celgene, Dermira, Forard Pharma, Janssen, LEO Pharma, Eli Lilly and Company, Marucho, MEdac, Novartis, Pfizer, Stiefel/GlaxoSmithKline, UCB Pharma and XenoPort. Please see the study for other researchers’ relevant financial disclosures.
Click Here to Manage Email Alerts